Leukemia

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were available to me.

While spending weeks in the hospital for acute myeloid leukemia, I tried eight fun things to keep me busy.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

From Danielle Fishel and Rick Steves announcing their diagnosis to the “Emily in Paris” star discussing her cancer experience, here’s what’s happening in the oncology space this week.

As I visit the cancer center for chemotherapy to treat my CLL, I can’t help but take note of how different cancer may look in each person.

Researchers have identified genetic differences that can make leukemia relapse more or less likely among pediatric patients.

Researchers compared health-related quality of life among patients ages 60 and older with acute myeloid leukemia undergoing different chemotherapy regimens.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

During chemotherapy for my chronic lymphocytic leukemia, I try my best to appreciate the positive aspects of life, like flowers and friends.

After receiving cancer treatment and leaving the hospital, sometimes it feels like a safety net has been pulled away and loneliness sets in.

During my chemotherapy treatments for chronic lymphocytic leukemia, I had a supportive group of people surrounding me.

From “Top Chef’” Shirley Chung and comedian Christina Pazsitzky announcing their diagnoses to Erica Ash’s death from the disease, here is what’s happening in the oncology space this week.

I kept picking at these possibilities, grasping for reasons why cancer was happening to me rather than someone else.

It’s easy to fall into depression and anxiety during long hospitalizations for cancer, but creativity helped pull me out of those negative feelings.

When I was diagnosed with leukemia in 2004, it was before the days of social media. However, I still found an online support group that was very helpful.

When eating, walking and bathing became difficult after cancer, my daughter stepped in. I was proud of who she had become.

An FDA fast track designation was granted to DSP-5336, a novel treatment for patients with relapsed or refractory AML with KMT2A gene rearrangements.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia had better MRD statuses after receiving Iclusig, compared with Gleevec.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

Being able to live independently and enjoy life’s beauty summon feelings of gratitude and euphoria more often now.

My oncologist said that having a supportive community during cancer is just as important as treatment and I could not agree more — it makes me thankful.

Patients with chronic lymphocytic leukemia had better survival when treated with Calquence during earlier lines of therapy.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma tended to be more likely to stay on treatment and experience fewer heart toxicities with Calquence or Brukinsa.

The FDA approved Blincyto for patients aged one month and older with CD19-positive, Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Through it all, poetry was the lens through which I could examine and deal with these very emotional and painful times in my life.

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Patients aged 80 and older are often excluded from receiving the standard regimen for acute myeloid leukemia. However, research showed that some patients can tolerate the therapy.

Here’s a look at therapies the FDA approved in the blood cancer space over the last few months.

When I was diagnosed and treated for a recurrence of AML, I was given an abundance of statistical information through required medical expert orations and accredited literature.